Investing.com -- AIM ImmunoTech (NYSE: AIM) Inc. (NYSE American: AIM) has announced its intention to develop Ampligen as a vaccine adjuvant for avian influenza. This move is part of AIM's antiviral ...

Freddie Farrow died after the ‘very large mirror’ fell on to him in the Fenwick department store in Colchester on July 27 ...

Downstream from the Ronald Reagan National Airport debris was picked from the Potomac River after a deadly collision between ...

People hold their mobile phone lights during a protest in front of Novi Sad railway station where 15 people were killed in a ...

So far, Health Canada has approved the Moderna Spikevax, Pfizer-BioNTech Cominarty, AstraZeneca Vaxevria and Janssen (Johnson & Johnson) vaccines ... % oil rate Hospital safety: Halifax Infirmary ...

In June 2007, AstraZeneca completed the acquisition of vaccine maker MedImmune ... right patient, right safety and right commercial. ‘Right patient’, for example, is about finding the patient ...

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

The vaccine has already shown evidence of safety and preliminary efficacy ... now on the label of AstraZeneca and Daiichi Sankyo's Enhertu. A GSK alliance with Oxford University aims to identify ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 78 tables and 119 figures, this 215-page report ?Global Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...